AstraZeneca's ASCO 'super sunday' delivers new data for Tagrisso and Imfinzi in lung cancer and Enhertu in breast cancer
AstraZenecaAZNannounced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway. P...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for which the companies have high expectations. The FDA on Fridayannouncedit had approved the drug, to ...
AstraZeneca Will Stop Selling Breast-Cancer Drug in June.Reports on the plan of AstraZeneca PLC to stop selling the breast-cancer drug tamoxifen under the brand name Nolvadex.DoorenJenniferCorbettEBSCO_bspWall Street Journal Eastern Edition
A drug from AstraZeneca tamped down the progression of breast cancer, after the same drug produced underwhelming results in lung cancer.
advanced or metastatic HR-positive/HER2-negative breast cancer who have PIK3CA, AKT1, or PTEN mutations and have progressed after endocrine therapy or relapsed within 12 months of completing adjuvant therapy. The drug can be prescribed in combination with fulvestrant, a common breast cancer medication...
AstraZeneca breast cancer drug gains marketing approval in EU.Reports that AstraZeneca PLC has received European marketing approval for its breast cancer drug Faslodex, which is indicated for the treatment of advanced breast cancer in post-menopausal women whose cancer has progressed on previous anti-...
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for patients with previously treated metastatic HR-positive, HER2-negative breast cance...
The company's Truqap, in combination with its endocrine therapy Faslodex, has been approved by the regulator for adult patients with advanced HR-positive breast cancer with specific biomarker alterations.
capivasertib and camizestrant as well as new data from antibody drug conjugates ENHERTU®(fam-trastuzumab deruxtecan-nxki) and datopotamab deruxtecan will underscore our focus on addressing the greatest unmet needs and delivering person...